

Evaristo Maiello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9043654/publications.pdf>

Version: 2024-02-01

155
papers

6,102
citations

66343

42
h-index

85541

71
g-index

157
all docs

157
docs citations

157
times ranked

8925
citing authors

#	ARTICLE	IF	CITATIONS
1	Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective. <i>Seminars in Cancer Biology</i> , 2022, 86, 997-1007.	9.6	8
2	Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. <i>Clinical Colorectal Cancer</i> , 2022, 21, 141-148.	2.3	10
3	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 820.	4.1	15
4	Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. <i>Cancers</i> , 2022, 14, 1168.	3.7	0
5	Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies. <i>Cancers</i> , 2022, 14, 1052.	3.7	2
6	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3871.	4.1	14
7	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. <i>Diagnostics</i> , 2022, 12, 685.	2.6	1
8	Immunotherapy in advanced anal cancer: Is the beginning of a new era?. <i>Cancer Treatment Reviews</i> , 2022, 105, 102373.	7.7	12
9	How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2022, 12, 844801.	2.8	7
10	Combined analysis of miR-200 family and its significance for breast cancer. <i>Scientific Reports</i> , 2021, 11, 2980.	3.3	22
11	Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1941.	3.7	21
12	Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 1749-1759.	2.4	0
13	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1529.	7.1	80
14	Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. <i>Frontiers in Genetics</i> , 2021, 12, 693933.	2.3	10
15	Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 4438.	3.7	40
16	Effectiveness and Safety of Transthoracic Ultrasound in Guiding Percutaneous Needle Biopsy in the Lung and Comparison vs. CT Scan in Assessing Morphology of Subpleural Consolidations. <i>Diagnostics</i> , 2021, 11, 1641.	2.6	6
17	Intraoperative Lung Ultrasound (ILU) for the Assessment of Pulmonary Nodules. <i>Diagnostics</i> , 2021, 11, 1691.	2.6	3
18	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in <i>RAS</i> wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 138, 1-10.	2.8	23

#	ARTICLE	IF	CITATIONS
19	Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. <i>ESMO Open</i> , 2020, 5, e000753.	4.5	25
20	Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 1415.	2.8	31
21	Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. <i>Clinical Colorectal Cancer</i> , 2020, 19, 270-276.	2.3	0
22	Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). <i>Breast</i> , 2020, 53, 18-22.	2.2	7
23	Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'€™Italia Meridionale (GOIM 2802). <i>Clinical Colorectal Cancer</i> , 2020, 19, 109-115.	2.3	6
24	Methylation Density Pattern of KEAP1 Gene in Lung Cancer Cell Lines Detected by Quantitative Methylation Specific PCR and Pyrosequencing. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2697.	4.1	15
25	Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel. <i>Scientific Reports</i> , 2019, 9, 14913.	3.3	19
26	Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2531.	4.1	15
27	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , 2019, 19, 283.	2.6	12
28	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
29	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 435-446.	1.4	9
30	RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. <i>Annals of Oncology</i> , 2018, 29, 112-118.	1.2	86
31	Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e457-e470.	2.3	18
32	Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-15.	1.5	28
33	Frequent <i>NRG1</i> fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. <i>Oncotarget</i> , 2018, 9, 9661-9671.	1.8	36
34	A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients. <i>Lung Cancer</i> , 2017, 108, 15-21.	2.0	10
35	Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. <i>Lung Cancer</i> , 2017, 111, 30-37.	2.0	27
36	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246.	2.8	38

#	ARTICLE	IF	CITATIONS
37	Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients. <i>Scientific Reports</i> , 2017, 7, 45283.	3.3	45
38	Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 587-594.	2.5	9
39	Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment. <i>EPMA Journal</i> , 2017, 8, 69-73.	6.1	7
40	ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, e161-e163.	1.1	16
41	Novel association of MEN1 gene mutations with parathyroid carcinoma. <i>Oncology Letters</i> , 2017, 14, 23-30.	1.8	16
42	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, 1357-1367.	1.1	144
43	Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1281-1288.	3.3	8
44	The potential role of nintedanib in treating colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1153-1162.	1.8	15
45	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017, 82, 16-24.	2.8	40
46	Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, e61-e72.	2.3	18
47	MEN1 gene mutation with parathyroid carcinoma: first report of a familial case. <i>Endocrine Connections</i> , 2017, 6, 886-891.	1.9	14
48	Phosphatidylinositol 3-kinase (PI3K)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. <i>Oncotarget</i> , 2017, 8, 76479-76491.	1.8	24
49	Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS810-TPS810.	1.6	3
50	MicroRNA co-expression networks exhibit increased complexity in pancreatic ductal compared to Vater's papilla adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 105320-105339.	1.8	9
51	Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 407-415.	1.3	28
52	Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2016, 6, 39565.	3.3	15
53	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1304-1312.	1.2	71
54	Phase III trial comparing 6 months of adjuvant FOLFOX4/XELOX in stage III colon cancer: safety and compliance in the TOSCA trial. <i>Annals of Oncology</i> , 2016, 27, 2074-2081.	1.2	44

#	ARTICLE	IF	CITATIONS
55	BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. <i>Cancer Biology and Therapy</i> , 2016, 17, 840-848.	3.4	17
56	Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. <i>Annals of Oncology</i> , 2016, 27, 1055-1061.	1.2	73
57	Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6287.	3.3	8
58	Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients. <i>Scientific Reports</i> , 2015, 5, 18592.	3.3	27
59	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 155-162.	3.1	27
60	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	8.6	65
61	Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo) Tj ETQq1 1 0.784314 rgBT /Overlo 262-273.	2.6	34
62	Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. <i>Annals of Oncology</i> , 2015, 26, 1710-1714.	1.2	120
63	Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and) Tj ETQq1 1 0.784314 rgBT /Overlo	2.6	34
64	A prospective study on survival in cancer patients with and without venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2014, 9, 559-67.	2.0	27
65	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	2.5	33
66	A MiRNA Signature for Defining Aggressive Phenotype and Prognosis in Gliomas. <i>PLoS ONE</i> , 2014, 9, e108950.	2.5	60
67	CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen. <i>International Journal of Molecular Sciences</i> , 2014, 15, 15767-15777.	4.1	20
68	Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III study. <i>International Journal of Oncology</i> , 2014, 45, 2137-2142.	3.3	22
69	Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. <i>Future Oncology</i> , 2014, 10, 725-733.	2.4	3
70	Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. <i>Journal of Translational Medicine</i> , 2014, 12, 248.	4.4	10
71	Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. <i>Molecular Cancer</i> , 2014, 13, 142.	19.2	40
72	Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. <i>Annals of Oncology</i> , 2014, 25, 1756-1761.	1.2	105

#	ARTICLE	IF	CITATIONS
73	Target Therapies in Pancreatic Carcinoma. <i>Current Medicinal Chemistry</i> , 2014, 21, 948-965.	2.4	43
74	Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?. <i>Medical Oncology</i> , 2013, 30, 578.	2.5	9
75	Chemokine receptor CXCR4: Role in gastrointestinal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 696-705.	4.4	48
76	Aberrant <i>Keap1</i> methylation in breast cancer and association with clinicopathological features. <i>Epigenetics</i> , 2013, 8, 105-112.	2.7	77
77	Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e74402.	2.5	56
78	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	2.5	66
79	Changes in miR-143 and miR-21 Expression and Clinicopathological Correlations in Pancreatic Cancers. <i>Pancreas</i> , 2012, 41, 1280-1284.	1.1	39
80	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. <i>Annals of Oncology</i> , 2012, 23, 2072-2077.	1.2	108
81	Combined modality treatments in pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S71-S81.	3.4	10
82	The Italian cross-sectional survey of the management of bone metastasis: ZeTa study. <i>Journal of Bone Oncology</i> , 2012, 1, 35-39.	2.4	2
83	CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. <i>Cellular Oncology (Dordrecht)</i> , 2012, 35, 411-422.	4.4	67
84	Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. <i>Annals of Oncology</i> , 2012, 23, 2313-2318.	1.2	170
85	Evidence-based guidelines: Improving AGREement on consistence evaluation. <i>Journal of Bone Oncology</i> , 2012, 1, 30-34.	2.4	0
86	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012, 48, 324-332.	2.8	84
87	Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. <i>BMC Cancer</i> , 2012, 12, 216.	2.6	6
88	Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S111-S117.	3.4	13
89	Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?. <i>Medical Oncology</i> , 2012, 29, 1908-1913.	2.5	15
90	Aberrant Genes Promoter Methylation in Neural Crest-Derived Tumors. <i>International Journal of Biological Markers</i> , 2012, 27, 389-394.	1.8	6

#	ARTICLE	IF	CITATIONS
91	Targeting EGFR in bilio-pancreatic and liver carcinoma. <i>Frontiers in Bioscience - Scholar</i> , 2011, S3, 16-22.	2.1	7
92	Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM). <i>Tumori</i> , 2011, 97, 559-563.	1.1	14
93	Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients. <i>Current Drug Metabolism</i> , 2011, 12, 918-931.	1.2	11
94	Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life-Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer (ERACLE). <i>Clinical Lung Cancer</i> , 2011, 12, 402-406.	2.6	11
95	Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. <i>Pharmacogenomics Journal</i> , 2011, 11, 429-436.	2.0	98
96	Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 435-441.	4.4	20
97	High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. <i>International Journal of Cancer</i> , 2011, 129, 536-545.	5.1	40
98	Temporal stability of alexithymia in cancer patients following a psychological intervention. <i>Journal of Clinical Psychology</i> , 2011, 67, 1177-1187.	1.9	19
99	Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. <i>Epigenetics</i> , 2011, 6, 710-719.	2.7	126
100	Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. <i>Oncologist</i> , 2011, 16, 228-238.	3.7	94
101	Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). <i>Annals of Oncology</i> , 2011, 22, 2424-2430.	1.2	57
102	Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 461-464.	1.3	40
103	Severe Spontaneous Acute Tumor Lysis Syndrome and Hypoglycemia in Patient with Germ Cell Tumor. <i>Tumori</i> , 2010, 96, 1040-1043.	1.1	19
104	Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1645-1651.	1.6	279
105	miR-192/miR-215 Influence 5-Fluorouracil Resistance through Cell Cycle-Mediated Mechanisms Complementary to Its Post-transcriptional Thymidilate Synthase Regulation. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2265-2275.	4.1	154
106	Alexithymia and Cancer Pain: The Effect of Psychological Intervention. <i>Psychotherapy and Psychosomatics</i> , 2010, 79, 156-163.	8.8	48
107	Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell'Italia Meridionale Multicenter Phase II Study. <i>Oncology</i> , 2010, 79, 415-422.	1.9	16
108	New molecular targets in bone metastases. <i>Cancer Treatment Reviews</i> , 2010, 36, S6-S10.	7.7	56

#	ARTICLE	IF	CITATIONS
109	Adjuvant colon cancer chemotherapy: where we are and where we'll go. <i>Cancer Treatment Reviews</i> , 2010, 36, S34-S41.	7.7	70
110	Update on capecitabine alone and in combination regimens in colorectal cancer patients. <i>Cancer Treatment Reviews</i> , 2010, 36, S46-S55.	7.7	15
111	Molecularly targeted endocrine therapies for breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, S67-S71.	7.7	61
112	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. <i>Cancer Treatment Reviews</i> , 2010, 36, S87-S94.	7.7	36
113	Changes in CpG Islands Promoter Methylation Patterns during Ductal Breast Carcinoma Progression. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2694-2700.	2.5	73
114	MicroRNAs as a New Potential Therapeutic Opportunity in Gastrointestinal Cancer. <i>Oncology</i> , 2009, 77, 75-89.	1.9	6
115	Evolution of Therapy Decision-Making Process for Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2009, 77, 97-102.	1.9	1
116	Adjuvant Therapy in Colon Cancer. <i>Oncology</i> , 2009, 77, 50-56.	1.9	13
117	KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 565-577.	3.1	10
118	High Specificity of Quantitative Methylation-Specific PCR Analysis for MGMT Promoter Hypermethylation Detection in Gliomas. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-8.	3.0	23
119	The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma. <i>Oncology</i> , 2009, 77, 69-74.	1.9	16
120	Clinical results of EGFR-targeted therapies in advanced colorectal cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 64-69.	2.2	1
121	Epirubicin, taxotere and fluorouracil modulated by folinic acid in the treatment of advanced gastric cancer: A phase II study of the Gruppo Oncologico dell' Italia Meridionale (GOIM). <i>European Journal of Cancer, Supplement</i> , 2008, 6, 107-112.	2.2	1
122	Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer (CRC) patients: A phase II study of the Gruppo Oncologico dell' Italia Meridionale (GOIM). <i>European Journal of Cancer, Supplement</i> , 2008, 6, 102-106.	2.2	12
123	Correlation between basal bilirubin levels and survival in advanced colorectal carcinoma treated with CPT-11-based chemotherapy: A study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). <i>European Journal of Cancer, Supplement</i> , 2008, 6, 94-99.	2.2	0
124	Cetuximab: clinical results in colorectal cancer. <i>Annals of Oncology</i> , 2007, 18, vi8-vi10.	1.2	12
125	Agreement between oncology guidelines and clinical practice in Italy: the "right" program. A project of the Italian Association of Medical Oncology (AIOM). <i>Annals of Oncology</i> , 2007, 18, vi179-vi184.	1.2	11
126	Cetuximab in squamous cell head and neck carcinomas. <i>Annals of Oncology</i> , 2007, 18, vi5-vi7.	1.2	13

#	ARTICLE	IF	CITATIONS
127	Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM) Tj ETQq1 1107843143gBT /Ove	1.2	47
128	Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. <i>Annals of Oncology</i> , 2007, 18, vi124-vi127.	1.2	47
129	Role of external radiation therapy in urinary cancers. <i>Annals of Oncology</i> , 2007, 18, vi157-vi161.	1.2	4
130	Genomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinoma. <i>Cancer Letters</i> , 2007, 254, 298-307.	7.2	50
131	Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. <i>Annals of Oncology</i> , 2007, 18, vi66-vi69.	1.2	24
132	Alexithymia, coping, and illness behavior correlates of pain experience in cancer patients. <i>Psycho-Oncology</i> , 2007, 16, 644-650.	2.3	47
133	Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicenter Experience. <i>Clinical Colorectal Cancer</i> , 2006, 5, 422-428.	2.3	30
134	Postchemotherapy residual masses in germ cell tumor patients: our experience. <i>Annals of Oncology</i> , 2006, 17, vii132-vii136.	1.2	3
135	FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). <i>Annals of Oncology</i> , 2006, 17, vii55-vii59.	1.2	24
136	Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). <i>Annals of Oncology</i> , 2006, 17, vii73-vii77.	1.2	30
137	Irinotecan (CPT-11) and Mitomycin-C (MMC) as Second-Line Therapy in Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 581-585.	1.3	39
138	FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). <i>Annals of Oncology</i> , 2005, 16, iv56-iv60.	1.2	13
139	Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell'™Italia Meridionale. <i>Journal of Clinical Oncology</i> , 2005, 23, 4866-4875.	1.6	693
140	Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. <i>International Journal of Cancer</i> , 2004, 111, 252-258.	5.1	42
141	Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen. <i>Melanoma Research</i> , 2003, 13, 73-79.	1.2	11
142	Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma. <i>Cancer</i> , 2002, 94, 902-910.	4.1	347
143	Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma. <i>Cancer</i> , 2002, 94, 902-910.	4.1	29
144	Treatment of Inoperable and/or Metastatic Biliary Tree Carcinomas With Single-Agent Gemcitabine or in Combination With Levofolinic Acid and Infusional Fluorouracil: Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 4089-4091.	1.6	126

#	ARTICLE	IF	CITATIONS
145	5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomised phase II study of the Southern Italy Oncology Group. <i>Annals of Oncology</i> , 2000, 11, 1045-1052.	1.2	33
146	5-Fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma. <i>Cancer</i> , 1999, 85, 535-545.	4.1	16
147	5-Fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma. <i>Cancer</i> , 1999, 85, 535-545.	4.1	3
148	Epirubicin, Folinic Acid, Fluorouracil, and Etoposide in the Treatment of Advanced Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 262-266.	1.3	5
149	Epidoxorubicin and Double Biochemical 5-Fluorouracil Modulation with Folinic Acid and Human Lymphoblastoid Interferon in Advanced Gastric Carcinoma: A Multicentric Phase II Study of the Southern Italy Oncology Group (GOIM). <i>Oncology</i> , 1996, 53, 269-274.	1.9	3
150	A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 151-159.	2.5	51
151	Efficacy of the Association of Folinic Acid and 5-Fluorouracil Alone Versus Folinic Acid and 5-Fluorouracil Plus 4-Epidoxorubicin in the Treatment of Advanced Gastric Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1995, 18, 519-524.	1.3	17
152	Sequential Treatment with High-Dose Methotrexate and Fluorouracil in Advanced Colorectal Cancer. Experience of The Southern Italian Oncology Group (GOIM). <i>Journal of Chemotherapy</i> , 1994, 6, 139-146.	1.5	0
153	Sequential methotrexate/5-fluorouracil in advanced colorectal cancer treatment. <i>Journal of Surgical Oncology</i> , 1991, 48, 129-133.	1.7	3
154	Comparison of CHOP-B vs CEOP-B in "poor prognosis" non-Hodgkin's lymphomas. A randomized trial. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1989, 6, 163-169.	1.1	21
155	Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1988, 11, 31-36.	2.5	16